Before 2023, There Was No Treatment for Geographic Atrophy.

Qdata® Can Change the Future of Managing this Condition.

Qdata Geographic Atrophy (GA) unlocks new real-world research possibilities by linking EHR and ophthalmic imaging data for a comprehensive view into the GA patient journey. Get exclusive access to curated variables such as visual acuity, subfoveal involvement and more for 810,000+ patients.

About Qdata

Qdata® by Verana Health are research ready, fit-for-purpose data modules designed to confidently drive business insights and inform research outcomes. Qdata spans ophthalmology, neurology, and urology to help unlock quality insights across the entire drug and device development cycle.

animated magnifying glass icon

Exclusive Coverage of the GA Patient Population


High-quality, Image-derived Insights

animated person atop arrow icon

Comprehensive View into Disease Progression & Severity

Only found here from the IRIS® Registry (Intelligent Research in Sight)

Using novel machine learning and computer vision algorithms

From diagnosis to subfoveal involvement and more


By the Numbers


Total de-identified patients with GA*


GA patients with linked ophthalmic images


Clinicians contributing

close-up of aged female eye

*Defined as patients who are 50 years or older and who have an ICD-10 code for GA (H35.31x3,4) or ICD-code for age-related macular degeneration (AMD) and either an image or clinical note indicating geographic atrophy between January 2013 and September 2023. Data current to September 2023.

Meet with a Qdata Expert or Request a Data Count

Key Variables in Qdata Geographic Atrophy

Curated variables extracted from EHR data and/or images to be utilized based on your research needs.

GA Diagnosis

Visual Acuity

Subfoveal Involvement

Lesion Size

Lesion Count

Lesion Growth Rate

Unstructured Data Enables Deeper Understanding

Verana Health applies clinician-informed algorithms to unstructured EHR data and ophthalmic images at scale to extract key information such as visual acuity, lesion size, count and growth rate, subfoveal involvement and more.

This can give life sciences companies unprecedented insights into the GA patient journey, GA disease progression, as well as track treatment patterns and outcomes as more therapies come to market.


of Medical Data Remains Unstructured


Talk to a Qdata Expert

Take a minute to submit your contact information and one of our team members will reach out to you.